Discover Pfizer's Q1 2025 earnings insights, including strategic R&D updates, financial guidance, and cost-saving initiatives.

Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its ...

Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Pfizer stock jumped Tuesday after the S&P 500 drugmaker beat first-quarter profit expectations on the back of savvy ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...